Address
910 Clopper Road
Gaithersburg, MD 20878
United States of America (the)
Phone
240 654 1450
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
May 26, 2017
| Name | Title | Pay | Year Born |
| Jerome Benedict Durso | Chairman, CEO & President | 50,941 | 1968 |
| Christophe Arbet-Engels | Chief Medical Officer | 361,356 | 1963 |
| Raymond Jordt | Chief Business Officer | 578,850 | 1973 |
| Gregory L. Weaver | Chief Financial Officer | 619,694 | 1956 |
| Scot Roberts | Chief Scientific Officer | 683,229 | 1959 |
| Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | 0 | 1988 |
| Bertrand Georges | Chief Technology Officer | 0 | N/A |
| Tony Blandin | Vice President of Quality & Compliance Management | 0 | N/A |
| Robin E. Abrams | Chief Legal Officer & Corporate Secretary | 0 | 1964 |
| Linda Richardson | Chief Commercial Officer | 0 | 1964 |
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.